Stock CMPX COMPASS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Compass Therapeutics, Inc. OTC Markets

Equities

CMPX

US20454B1044

Delayed OTC Markets
Other stock markets
 15:59:57 2021-11-03 EDT 		5-day change 1st Jan Change
3.55 USD -10.80% Intraday chart for Compass Therapeutics, Inc. +32.67% -.--%
05-13 Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-06 Top Premarket Gainers MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
AQ
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
AQ
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Top Premarket Gainers
MT
Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment
MT
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment
DJ
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
AQ
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
CI
Compass Therapeutics : 2024 Proxy
PU
Compass Therapeutics : Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data
PU
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
MT
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
AQ
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
CI
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
AQ
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
AQ
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
AQ
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
AQ
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPX Stock
  4. CMPX Stock
  5. News Compass Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW